Absci Corp

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Absci Corp reports solid Q1 performance, highlights platform efficiency

Absci Corp's Q1 2024 performance reflects a focus on innovation with significant R&D investment and revenue generation, supported by a strong cash position
The company's hybrid business model and progress on internal pipeline programs showcase efficiency and commitment to advancing multiple therapeutic candidates

Absci Corp reports strong Q2 earnings, expands oncology programs

Absci Corp's Q2 2024 earnings call highlighted strong financials, progress in pipeline programs, and strategic collaborations with MSK and other partners.
The company's focus on immunology and oncology, supported by AI capabilities and a healthy cash position, positions Absci for future growth and innovation.
While facing challenges in managing R&D expenses and advancing validation studies, Absci has opportunities to drive innovation and establish a leading position in the market.
Overall, Absci's performance in Q2 2024 reflects a company poised for growth, with a solid foundation to drive research, development, and strategic partnerships.

Absci Corp reports solid Q3 earnings, eyes strategic partnerships for growth

Absci Corp's Q3 2024 performance reflects steady revenue growth, prudent cost management, and strong cash reserves.
The company's strategic collaborations and upcoming R&D Day signal a focus on innovation, partnerships, and future growth.
While challenges in managing expenses persist, Absci Corp's opportunities lie in expanding partnerships, showcasing technology, and driving market interest.
Overall, Absci Corp's emphasis on execution, upcoming catalysts, and financial discipline positions it for continued success in the biotech sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?

VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets.

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming 26th Annual Needham Growth Conference.

Absci to Participate in the 26th Annual Needham Growth Conference

VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Active Programs signed for the year VANCOUVER, Wash., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs.

Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy

Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

AstraZeneca

Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.

AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT

VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.

Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference

Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties

Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results

BARCELONA, Spain & VANCOUVER, Wash.--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci's Integrated Drug Creation™ platform with Almirall's dermatological expertise wi.

Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases

VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day on Wednesday, October 4th, 2023.

Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen

VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on Wednesday, October 4th, 2023 in New York City. The program will begin at 9:00 a.m. Eastern Time and feature presentations from members of Absci's leadership team as well as guest speakers, followed by an interactive Q&A session. The program is expected to conclude at approximately 12:00 p.m. Eastern Time.

Absci to Host R&D Day on October 4, 2023

Publicly traded biotech company Absci is laying off 30 employees, or approximately 15% of its workforce.

Biotech company Absci lays off 30 employees, about 15% of staff

Purple Innovation

22nd Century Group

Penny stocks are often defined as stocks trading under $5 per share, those with a very low price per share or market capitalization, and are generally higher-risk. Now, despite many such stocks certainly carrying a relatively high risk profile, this often is somewhat offset by higher potential returns.

The 3 Most Undervalued Penny Stocks to Buy Now: August 2023

Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech, supported by the Gates Foundation, to discover affordable HIV therapeutic vaccinations VANCOUVER, Wash. and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended June 30, 2023.

Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

Addition of veteran biotech leader to further support Absci's next stage of growth Addition of veteran biotech leader to further support Absci's next stage of growth

Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer

VANCOUVER, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, today announced that leading researchers at the California Institute of Technology (Caltech) in conjunction with Absci, a leader in AI drug creation, received a grant from the Bill & Melinda Gates Foundation. The grant supports the joint effort of Caltech and Absci to discover affordable HIV therapeutic vaccinations, with the goal of making a significant step forward in the fight against the global HIV/AIDS epidemic.

Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming UBS MedTech, Tools and Genomics Summit 2023 in Dana Point, CA.

Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023

VANCOUVER, Wash. and NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Morgan Stanley 2nd Annual Biotechnology AI Summit in New York, NY.

Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit

VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory.

Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

Absci Corporation (ABSI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.33 per share a year ago.

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate

Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results

Absci will apply its generative AI platform to The Kennedy Institute's immunology biorepository to speed the discovery and development of multiple therapies Absci will apply its generative AI platform to The Kennedy Institute's immunology biorepository to speed the discovery and development of multiple therapies

News for Absci Corp Stock (ABSI)